中西药联用治疗失代偿肝硬变临床研究

Clinical Study of Chinese Plus Western Medication in the Treatment of Decompensated Cirrhosis

目的 :观察拉米呋啶联合苦参素治疗失代偿肝硬变的疗效的安全性。方法 :在综合治疗的基础上 ,每次口服拉米呋啶1 0 0mg ,肌注苦参素针 4 0 0mg ,共 6个月。结果 :治疗组肝功明显改善并保持稳定 ,HBVDNA定量显著下降 ,Child -Pugh得分显著下降。结论 :拉米呋啶联合苦参素能有效地控制失代偿肝硬化的炎症活动 ,逆转其失代偿状态 ,减少并发症 。

Objective: To observe the efficacy and safeness of lamivudine plus kurarinone in the treatment of decompensated cirrhosis. Method: On the basis of general treatment, the patients were given 100 mg lamivudine at one time for oral administration, and 400mg kurarinone for intramuscular injection continuously for six months. Result: The liver function in the treatment group obviously improved and maintained stability, with a marked decrease in HBVDNA quantity and Child Pugh. Conclusion: This indicates that lamivudine plus kurarinone can effectively control the inflammatory activity due to decompensated cirrhosis, reverse the decompensated status, reduce complicating diseases, and has little side effect.